BiotechTube
Pentabase

Pentabase

Copenhagen, Denmark· Est.
pentabase.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

PentaBase is a private, revenue-generating diagnostics company leveraging its proprietary INA® (Intercalating Nucleic Acid) chemistry to create superior PCR-based assays for oncology. Its core technology enables highly sensitive and specific detection of genetic mutations and methylation patterns, which is critical for cancer diagnostics and monitoring. The company has a portfolio of commercial products, including CE-IVD kits for targets like MGMT and MYD88, and also operates a custom oligonucleotide design and manufacturing business. Headquartered in Copenhagen, Denmark, PentaBase serves a global market through a distributor network.

Oncology

Technology Platform

Proprietary INA® (Intercalating Nucleic Acid) chemistry, featuring oligonucleotides heavily modified with intercalating pseudo-nucleotides (IPNs). This platform enables the creation of high-affinity, high-specificity tools like BaseBlockers™ (for blocking wild-type amplification) and EpiPrimers™ (for bisulfite-free DNA methylation detection), enhancing PCR assay sensitivity and specificity for cancer diagnostics.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The growing demand for liquid biopsy and minimal residual disease (MRD) monitoring plays directly to the strength of PentaBase's BaseBlocker™ technology, which excels at detecting low-frequency mutations.
Furthermore, the shift towards epigenetic markers and the need for simpler, more robust assays creates a significant opportunity for its bisulfite-free EpiDirect® platform to gain market share.

Risk Factors

PentaBase faces intense competition from large, well-resourced diagnostics corporations and alternative technology platforms like digital PCR and NGS.
Clinical adoption and favorable reimbursement for its specialized kits are non-trivial hurdles that can limit commercial growth despite technical superiority.

Competitive Landscape

PentaBase competes in the crowded molecular diagnostics space against giants like Roche, Qiagen, and Bio-Rad, as well as other specialty PCR companies. Its differentiation hinges on the unique performance advantages of its INA® chemistry for specific applications like mutation blocking and direct methylation detection, carving out a niche within the broader PCR and oncology diagnostics market.

More companies in Diagnostics & Precision Medicine →More companies in Denmark →